MacroGenics, Inc. (MGNX)
| Market Cap | 215.89M |
| Revenue (ttm) | 71.67M |
| Net Income (ttm) | -217.29M |
| Shares Out | 61.33M |
| EPS (ttm) | -3.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 382,268 |
| Open | 3.44 |
| Previous Close | 3.42 |
| Day's Range | 3.41 - 3.55 |
| 52-Week Range | 2.13 - 28.19 |
| Beta | 2.15 |
| Analysts | Buy |
| Price Target | 28.90 (+721.0%) |
| Earnings Date | Aug 4, 2022 |
About MGNX
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugat... [Read more...]
Financial Performance
In 2021, MacroGenics's revenue was $77.45 million, a decrease of -26.16% compared to the previous year's $104.88 million. Losses were -$202.12 million, 55.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price forecast is 28.9, which is an increase of 721.02% from the latest price.
News
Why MacroGenics Stock Is Skyrocketing Today
Investors like that a key insider is buying shares of the biotech.
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the tr...
MacroGenics Announces Appointment of William Heiden to Board of Directors
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the tre...
Why MacroGenics Stock Is Tanking Today
Investors found plenty to dislike about the company's Q1 update.
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
ROCKVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the tr...
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the t...
MacroGenics Announces Executive Promotion
ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the tr...
Why MacroGenics Stock Is Sinking Today
The company provided a disappointing Q4 update.
MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
ROCKVILLE, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the t...
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics...
Synaffix, MacroGenics Ink Pact For Next Generation Antibody-Drug Conjugates
Synaffix BV has entered into a technology agreement with MacroGenics Inc MGNX. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
MacroGenics (MGNX) Reports Q3 Loss, Misses Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -36.51% and -60.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
ROCKVILLE, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics...
Wall Street Analysts See a 69% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 69.5% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the posi...
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combinat...
SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat...
MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation
MacroGenics Inc (NASDAQ: MGNX) announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was presented at the 2021 European Society f...
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presente...
ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combinatio...
ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...
MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?
MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i...